Actithera

Actithera is an emerging radiopharmaceutical company leveraging a proprietary chemistry platform to design novel radioligand therapies (RLTs) with prolonged tumor retention. Its core strategy involves using covalent chemistries to create irreversible bonds with tumor-associated proteins, aiming to deliver more effective radiation with fewer treatment cycles and reduced toxicity. Founded by CEO Andreas Goutopoulos and backed by a syndicate of European life science venture capital firms, the company is in the preclinical stage, advancing its platform towards clinical development for cancers with high unmet need. Actithera's approach is isotope-agnostic, allowing flexibility in pairing radionuclides with targeting molecules based on tumor biology.

Proprietary chemistry platform focused on prolonging tumor retention of radioligands, utilizing covalent chemistry to create irreversible bonds with tumor-associated proteins. The platform is isotope-agnostic, allowing flexible pairing of targeting molecules (small molecules/peptides) with therapeutic radionuclides.

Actithera competes in the crowded and fast-moving radiopharmaceutical therapeutics sector, against giants like Novartis and a multitude of biotechs (e.g., RayzeBio, Fusion Pharmaceuticals, Perspective Therapeutics). Its differentiation hinges on its proprietary covalent chemistry for prolonged tumor retention, a approach not widely employed in current clinical-stage RLTs.